10-QPeriod: Q3 FY2024

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2024

Filed October 18, 2024For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported strong third-quarter results for the period ending September 29, 2024, demonstrating robust top-line growth and improving profitability. Total revenue surged 17% year-over-year to $2.04 billion, fueled by significant increases in both instruments and accessories revenue (+18%) and systems revenue (+17%). This growth was primarily driven by a 17% increase in total da Vinci procedures and the successful launch and placement of 110 new da Vinci 5 systems during the quarter. The company also reported a substantial increase in operating income, up 24% to $577 million, reflecting improved gross margins to 67.4% and effective management of operating expenses. This strong financial performance, coupled with a growing installed base of da Vinci and Ion systems, positions Intuitive Surgical favorably. The company maintains a healthy balance sheet with $8.31 billion in cash, cash equivalents, and investments, providing ample resources for continued investment in innovation and global expansion.

Financial Highlights

46 data points
Beta

Revenue

$2.04B

67.4% Gross Margin

Net Income

$565.10M

27.7% Net Margin

EPS (Diluted)

$1.56

Total Assets

$17.74B

Cash & Equivalents

$2.41B

Free Cash Flow

$706.50M

Financial Statements
Beta
Revenue$2.04B
Cost of Revenue$664.20M
Gross Profit$1.37B
R&D Expenses$286.00M
SG&A Expenses$510.60M
Operating Expenses$796.60M
Operating Income$577.30M
Net Income$565.10M
EPS (Basic)$1.59
EPS (Diluted)$1.56
Shares Outstanding (Basic)355.80M
Shares Outstanding (Diluted)362.70M

Key Highlights

  • 1Total revenue increased 17% year-over-year to $2.04 billion, driven by strong performance in instruments and accessories, systems, and service revenue.
  • 2Da Vinci procedures grew 18% year-over-year, demonstrating continued adoption and utilization of the company's robotic surgical systems.
  • 3Systems revenue saw a 17% increase, supported by a 17% rise in da Vinci system placements (379 systems placed in Q3 2024) and the introduction of the da Vinci 5 system.
  • 4Operating income grew significantly by 24% to $577 million, reflecting improved gross profit margins and disciplined expense management.
  • 5The installed base of da Vinci systems expanded by 15% to approximately 9,539 systems, indicating sustained market penetration.
  • 6Ion system procedures saw substantial growth of 73%, reflecting increasing adoption of the endoluminal system.
  • 7The company ended the quarter with a strong liquidity position, holding $8.31 billion in cash, cash equivalents, and investments.

Frequently Asked Questions

Revenue growth was primarily driven by a 17% increase in total da Vinci procedures performed, a 17% rise in systems revenue due to increased system placements (including the new da Vinci 5 system), and an 18% increase in instruments and accessories revenue, which is closely tied to procedure volume. Service revenue also contributed positively with an 12% increase.

The company placed 110 da Vinci 5 systems in the third quarter of 2024, contributing to the overall 17% increase in systems revenue. This new generation system, featuring advanced capabilities like force feedback, is part of the company's strategy to drive future growth and upgrade cycles.

Procedure volumes continue to show strong growth (18% for da Vinci procedures in Q3). While the company highlights factors like hospital staffing shortages and financial pressures which may lead to cautious capital spending, the overall procedure growth indicates resilience and continued adoption of minimally invasive care. The Ion system also demonstrated significant growth in procedures (73%).

Intuitive Surgical maintains a strong financial position with $8.31 billion in cash, cash equivalents, and investments as of September 30, 2024. This robust liquidity provides ample resources to fund operations, invest in research and development, and pursue growth opportunities.